شرح

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 میلیون از 2022 به 2028, جمع آوری CAGR از 16.1% در طول دوره پیش بینی.

این گزارش داده های به روز اندازه بازار را برای دوره ارائه می دهد 2018-2021 و پیش بینی به 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, کاربرد, biomarker type, فن آوری, و منطقه. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), دیگران (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 و پیش بینی می شود در طول دوره پیش بینی سهم خود را حفظ کند. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, دیگران. که در 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), دیگران. میان اینها, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. از نظر جغرافیایی, the global liquid biopsy market has been segmented into Asia Pacific, اروپا, آمریکای شمالی, بقیه دنیا (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., Becton Dickinson and Company, Berry Genomics Co. Ltd., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

این گزارش منبع ارزشمندی برای شرکت ها و سازمان های فعال در این صنعت است. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, سیاست گذاران, علمی, و تحلیلگران.

دامنه گزارش

Therapy: oncology, noninvasive prenatal testing (NIPT), دیگران (e.g. organ transplant)
کاربرد: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, دیگران
فن آوری: next-generation sequencing (NGS), polymerase chain reaction (PCR), دیگران
منطقه: آسیا و اقیانوسیه, اروپا, آمریکای شمالی, بقیه دنیا (RoW)
سال در نظر گرفته شده است: این گزارش دوره را پوشش می دهد 2018 به 2028

مزایای کلیدی برای ذینفعان

– Get a comprehensive picture of the global liquid biopsy market
– بخش های رشد و روند سرمایه گذاری را مشخص کنید

فهرست مطالب

قسمت 1. معرفی
– محدوده مطالعه
– دوره تحصیل
– محدوده جغرافیایی
– روش تحقیق
قسمت 2. Liquid biopsy market overview
قسمت 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– دیگران (e.g. organ transplant)
قسمت 4. تفکیک بازار بر اساس برنامه
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
قسمت 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– دیگران
قسمت 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– دیگران
قسمت 7. تفکیک بازار بر اساس منطقه
– آسیا و اقیانوسیه
– اروپا
– آمریکای شمالی
– بقیه دنیا (RoW)
قسمت 8. شرکت های کلیدی
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Ltd.
– Becton, Dickinson and Company
– Berry Genomics Co., Ltd.
– BGI Group
– Biocartis Group
– Biocept, شرکت.
– Biodesix, شرکت.
– Biolidics Limited
– Bio-Rad Laboratories, شرکت.
– Bio-Techne Corp.
– CareDx, شرکت.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, شرکت.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, شرکت.
– NeoGenomics Laboratories, شرکت.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, شرکت.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
درباره StrategyHelix
سلب مسئولیت